Roivant’s $7B Roche deal was a ‘moment of opportunity,’ CEO says

The acquisition of Telavant and its TL1A drug was born out of a J.P. Morgan conference meeting, Roivant chief executive Matt Gline said, and reflects the biotech’s flexible business strategy.